Study finds, Subretinal Injection of Recombinant Tissue Plas
A Study was conducted to analyse the efficacy of subretinal injection of recombinant tissue plasminogen activator (rtPA) and gas tamponade for the displacement of submacular haemorrhage (SMH).

Study included 25 consecutive patients (25 eyes) who underwent pars plana vitrectomy (PPV) with subretinal rtPA injection and 20% sulphur hexafluoride (SF6) tamponade. The primary outcome was SMH displacement rate, defined as the absence of subretinal blood within (complete) or outside (partial) 1500 microm centred on the fovea one month after PPV.

--Successful displacement was obtained in all 25 eyes, with complete and partial displacement obtained in 15 nd 10, respectively.

--BCVA significantly improved from 1.81± 0.33 to 1.37± 0.52 LogMar at 12 months from surgery.

--The bivariate correlation analysis revealed that earlier the surgery had better visual prognosis at the end of the follow-up.

--SMH recurrence was observed in 2 patients with a mean survival time of 11.6 ± 0.339 months and a cumulative survival probability of 88% at the end of follow-up.

--After PPV, the mean number of anti-VEGF injections was 3.00 ± 0.957 with no correlation with final visual acuity.

Finally, PPV combined with rtPA subretinal injection and SF6 tamponade is a safe and effective treatment for acute SMHs caused by neovascular AMD. To obtain BCVA improvement at 12 months and good imaging to plan future anti-VEG treatment, it is recommended to perform within 14 days after the onset of symptoms.